Pharmacognosy intro
Cinnamomum verum J.Presl (syn. C. zeylanicum Blume), Lauraceae. Inner bark (cortex). Common names include Ceylon cinnamon and true cinnamon. The critical species distinction from C. cassia (Chinese cinnamon) determines both safety and therapeutic value. The essential oil is dominated by trans-cinnamaldehyde (60-90%), with secondary compounds including eugenol, linalool, procyanidin type-A polymers (cinnamtannin B1), coumarin (trace in Ceylon, high in cassia), and cinnamic acid. Procyanidins contribute insulin-mimetic and antioxidant activity independent of cinnamaldehyde. Cinnamaldehyde and procyanidins activate insulin receptor kinase, enhancing glucose uptake via GLUT4 translocation and increasing glycogen synthesis through PPARgamma agonism comparable to thiazolidinedione drugs. Anti-inflammatory activity proceeds through NF-kappaB inhibition, NLRP3 inflammasome suppression, ERK1/2-MEK modulation, and Nrf2 pathway activation. Cinnamaldehyde is metabolized hepatically to sodium benzoate (NaB), which crosses the blood-brain barrier and increases BDNF and neurotrophin-3 production via the PKA/CREB pathway. NaB also inhibits p21ras activation, reducing NF-kappaB signaling in neural tissue. Cinnamaldehyde is a TRPA1 receptor agonist, producing the characteristic warming sensation. Human clinical evidence is strongest for glycemic control. A meta-analysis of 24 RCTs found cinnamon supplementation significantly reduced fasting blood sugar (SMD: -1.32), HOMA-IR (SMD: -1.32), and HbA1c (SMD: -0.67) in type 2 diabetes patients (Moridpour et al., 2023). A separate trial of 160 T2DM patients receiving 3 g/day C. verum for 3 months showed significant decreases in FPG (-10.09 mg/dL, p=0.001), HbA1c (-0.20%, p=0.001), and HOMA-IR (-0.47, p=0.006). An RCT with 50 migraine patients found 1800 mg/day cinnamon for 2 months significantly reduced serum IL-6 and NO levels, decreasing frequency, severity, and duration of migraine attacks versus placebo (Zareie et al., 2020). Preclinical neuroprotective findings include inhibition of tau protein aggregation relevant to Alzheimer's disease, protection of dopaminergic neurons through preservation of Parkin and DJ-1 proteins in Parkinson's models, and reduction of neuroinflammation through TLR4/NF-kappaB and NLRP3 pathways. Ceylon cinnamon (low coumarin) is the recommended species for all therapeutic dosing; cassia coumarin is hepatotoxic and potentially carcinogenic above 0.1 mg/kg body weight/day.